enGene's Non-Viral Gene Therapy for Bladder Cancer Heads to the FDA
On November 11, 2026, enGene Therapeutics reported updated results from the pivotal cohort of its LEGEND trial and said it will begin submitting a Biologics License Application (BLA) to the FDA for detalimogene voraplasmid by the end of 2026. Detalimogene is a non-viral gene therapy for people with high-risk non-muscle invasive bladder cancer (NMIBC) that no longer responds to the standard immunotherapy, BCG.
enGene, based in Boston and Montreal, says it aligned with the FDA on the key parts of the application at a pre-BLA meeting. It expects to complete the submission in the first half of 2027, with a potential approval later that year.
The patients this is for
Most bladder cancers are caught while they are still confined to the inner lining of the bladder. This is NMIBC. The standard treatment for high-risk NMIBC is BCG, a weakened tuberculosis bacterium that is put directly into the bladder to stir up an immune attack on the cancer.
When BCG stops working, the disease is called BCG-unresponsive. The main fallback is a radical cystectomy: surgery to remove the whole bladder, which then means living with a urinary diversion. LEGEND Cohort 1 enrolled people with BCG-unresponsive NMIBC with carcinoma in situ (CIS), a flat, aggressive form of the cancer, with or without papillary tumors.
How detalimogene works
Detalimogene is a circular piece of DNA, called a plasmid, packaged with enGene's DDX platform, which is based on a modified form of chitosan, a sugar-based polymer. No virus is involved. The medicine is instilled directly into the bladder through a catheter, the same way BCG is given.
Cells of the bladder lining take up the DNA and use its instructions to switch on a local immune response against the tumor, right where the cancer is. Because it is non-viral, enGene designed it to be simpler to make, store and give than virus-based gene therapies.
The updated results
As of the October 29, 2026 data cutoff, Cohort 1 had enrolled 125 patients, of whom 120 could be evaluated for efficacy.
56% had a complete response (no detectable cancer) at any time, up from 54% in April 2026.
24% were in complete response at the 12-month landmark, up from 13%.
The median duration of response was 10.1 months, and the preliminary estimate of responses lasting at least 12 months was 43%.
97% of evaluable patients did not progress to muscle-invasive disease, and 86% still had their bladder.
Safety
Of the 125 patients, 59% had at least one treatment-related side effect, mostly mild or moderate. The most common were fatigue (21%), painful urination (16%), frequent urination (16%) and bladder spasms (13%). Grade 3 treatment-related side effects occurred in 4% of patients, serious ones in 2%, and only 1% stopped treatment because of side effects. There were no grade 4 or 5 events.
What to watch
Detalimogene has the FDA's Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. It would join a fast-growing list of bladder-sparing options for BCG-unresponsive NMIBC, including Adstiladrin (nadofaragene firadenovec), an adenovirus-based gene therapy approved in 2022.
The key questions are how long responses last with more follow-up, and how the FDA weighs a 56% complete response rate and a 24% one-year rate against other options. Read more about how gene therapies get delivered into cells.
The bottom line
enGene's non-viral gene therapy cleared more than half of the evaluated bladder cancers that no longer respond to BCG, and most patients kept their bladders. With FDA alignment on the key parts of its application, the company plans to start its BLA by the end of 2026, which could make detalimogene the first non-viral gene therapy approved for bladder cancer.
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Watch: 30-second gene therapy Shorts and in-depth lessons on Gene Tech Times Academy.
New to gene therapy? Start with The Life-Changing Power of Gene Therapy.
Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.
As an Amazon Associate, Gene Tech Times earns from qualifying purchases.
— T.N., Gene Tech Times
Comments